A lot of biosimilar sponsors and wannabes are watching as the biosimilar competition in the U.S. unfolds to challenge the all-time biggest-selling drug, Humira from Abbvie Inc. While the competition started at the beginning of the year with the launch of Amgen’s Amjevita, the true test of the strength of the competition is taking place now as other adalimumab biosimilars hit the market. There are eight launching a challenge to Humira and all are likely to have a lower price tag than Humira’s. Discussing the biosimilars landscape with BioWorld Staff Writer Lee Landenberger are BioWorld Regulatory Editor Mari Serebrov, who has written extensively about biosimilars and these launches, and also Tom Newcomer, vice president and head of U.S. market access at Samsung Bioepis, which recently released its second quarterly report on biosimilar market penetration and pricing across various therapeutic spaces.